Holding Your Suppliers Accountable

Size: px
Start display at page:

Download "Holding Your Suppliers Accountable"

Transcription

1 Holding Your Suppliers Accountable What Defines an Ingredient Supplier of Choice? David R. Schoneker Director of Global Regulatory Affairs 0

2 Supply Chain Accountability Why and Why Now? The globalization of the dietary supplement industry and the multitude of sourcing locations have brought increased complexity to ensuring the integrity and quality of the ingredient supply chain Industry and regulatory systems have not evolved in accordance with changes in the supply chain Regulators expect the User of the ingredients (the dietary supplement manufacturer) to be responsible for the quality and safety of the ingredients that they use Therefore, it is critical that Users only work with high quality suppliers that they can TRUST can t just select suppliers based on price!

3 Definition of Supplier any active participant in the ingredient supply chain Manufacturer Distributor Re-packer Haulier...not just the company that you place the order with and pay!

4 Threats to the Supply Chain

5 Where do DS Ingredients come from? Diverse Materials Base Chemical synthesis (Polymer mixtures, Cellulose derivatives substances often less defined than low mol wt entities) Mining of minerals Harvesting of vegetation Formulated Products Biotechnology & Fermentation Genetic Modification Animal by-products

6 DS Ingredient Industry is significantly different than the Dietary Supplement Industry

7 Raw Materials may come from the farm or natural environment and are processed and packaged to become DS Ingredients

8 DS Ingredients are produced and packaged in many ways typically by chemical companies

9 The journey from the manufacturing site 8 The information contained in this presentation is proprietary to Colorcon and may not be used or disseminated inappropriately.

10 Increased Regulatory Expectations Supplier s Supplier Supplier s Supplier Supplier- Original Mfg Repacker Quality Risk Management Supplier Qualification Distributor Warehouse Dietary Supplement Manufacturer Security of Supply Chain Quality Agreements with Critical Material Suppliers The information contained in this presentation is proprietary to Colorcon and may not be used or Copyright disseminated 2015, inappropriately. All Rights Reserved IPEC-Americas

11 Effective Supply Chain Security Multiple components, all have to be in place to achieve the lowest risk: Material and Supplier Identity Supplier qualification Compliance Supply chain mapping from manufacturing plant to customer Risk management Business continuity planning (BCP) Focus on a single component alone, or in isolation, weakens the security chain

12 Why Quality Systems are Important? No amount of regulatory inspection or analytical testing by themselves can ensure the integrity or quality of a dietary supplement product Robust quality systems are required to provide this assurance Evaluation and oversight of vendors included in the ingredient supply chain is a critical element of a dietary supplement manufacturer s quality system Oates, Pfizer, Sept 08

13 Key Elements of Engagement with Vendors Selection of trustworthy vendors with strong quality systems Establishing clear expectations Ongoing collaboration with vendors across quality systems (e.g., changes, deviations) Routine trending and monitoring of vendor quality performance Routine on-site audits and visits (can be done using a qualified third party audit or certification body) Oates, Pfizer, Sept 08

14 Vendor Selection (Quality) Choose Carefully! Typically a two-step process to Establish TRUST: Step 1 Data-gathering (can be done remotely from vendor site) to collect information on the vendor s General quality systems and regulatory information (EIP, SIDI documents) Regulatory history (e.g., health authority approvals, inspection results, recalls) Current product mix Controls over their own supply chain Step 2 Due diligence audit physical audit vs. paper audit Must verify that the systems, organization, and facilities are sufficiently robust to assure quality risk assessment, appropriate GMPs for DS use, etc. Limiting factor Typically only have the ability to audit the application of vendor s quality systems to the materials being purchased Oates, Pfizer, Sept 08

15 Establishing Clear Expectations A clear and complete Quality Agreement is necessary to establish expectations for both you and your supplier Examples of items that may be part of a Quality Agreement Access to facilities Release process Change management Material purchase, receipt, storage, and testing Specifications and test methods Notification and approvals of deviations, out of specification results, and adverse trends Inspections by regulatory authorities Handling of rejected materials and/or products Product complaint handling Market actions Oates, Pfizer, Sept 08

16 Ongoing Collaboration with Vendors A risk assessment model may be used to determine the extent of oversight/involvement required in the Quality Agreement Allows resources expended to match the risk level Practical application of risk assessment output Vendors deemed to be of the highest risk may need to be eliminated from the supply chain Those in higher risk categories may require the highest level of oversight by the dietary supplement firm Highest quality (lowest risk) vendors may require less oversight Oates, Pfizer, Sept 08

17 Routine Monitoring and Trending Risk assessment of each supplier should be conducted on an ongoing basis to allow for the identification of trends and implementation of corrective actions Significant changes (planned or unplanned) at the vendor or other events may require a reassessment Vendors may move from one sector of the risk assessment matrix to another, resulting in the need for developing an exit strategy or applying more or less resources based on the change in risk profile Routine meeting held with key vendors is another way to monitor and influence quality performance Oates, Pfizer, Sept 08

18 Routine Audits and Visits A risk model similar to that described earlier to define extent of oversight can help determine the required frequency of audits and visits First, assess the quality risk Then take criticality of the material in the formulations where it is used into account A supplier you have never physically visited (or had a 3 rd party audit) should be considered your highest risk Paper audits are rarely enough except for very low risk suppliers but how can you assess risk without any physical audit information? Oates, Pfizer, Sept 08

19 How do you identify and control RISK in the excipient supply chain? For the RISK Not going to see the full picture from a certificate of analysis a questionnaire a label stating USP or FCC inspection on receipt lab analysis audit of the manufacturer audit of the distributor

20 RISK Knowing the true risk is the first step in preventing programs that look good on paper but offer only a false sense of security. You can t manage risk you don t see!.

21 Vulnerabilities in Industry Quality Systems: Concerns expressed by various Regulators Lack of traceability High complexity due to increased brokerage and trade activity Ingredient repackaged or relabeled multiple times Non-specific ID test frequently performed on composite sample Lack of verification of appropriate food and color additive status where applicable for use in DS Certificates of Analysis (CoAs) Over-reliance on CoAs Original manufacturer s CoA not always obtained CoA often altered to remove true identity of manufacturer Reported test results may be unreliable or falsified Rivera, FDA, Dec 08

22 Vulnerabilities (cont d) Supplier qualification programs, quality agreements, and lifecycle monitoring are often deficient Distant (foreign) manufacturing sites can pose special risks Audits of suppliers by dietary supplement manufacturers are superficial or not conducted at all Over-reliance on inspections by regulatory authorities Counterfeiting, i.e., deliberately and fraudulently mislabeling with respect to its identity or source Criminal substitution of cheaper ingredients in dietary supplement products Rivera, FDA, Dec 08

23 Measures to Ensure the Quality of the Supply Chain Implement a comprehensive approach to monitoring ingredient supply chain integrity Only do business with trustworthy sources Establish a robust supplier qualification program (e.g., vendor audits, quality agreements, appropriate ongoing QC of incoming lots, appropriate GMPs in place) Verify each ingredient shipment comes from approved suppliers/manufacturers and meet appropriate dietary ingredient or food/color additive regulatory requirements for use in DS Verify shipments came through expected routes and were not diverted Use specially designed tamper-evident container seals Thoroughly examine containers upon receipt for damage and evidence of tampering Insist on original authentic CoAs Refer to IPEC and CRN CoA Guides Rivera, FDA, Dec 08

24 Improving Key Elements in Quality System Clear, thorough communication of all requirements (not just specifications) and expectations from user Quality Agreements are useful Knowledge of supply chain pedigree from the ingredient manufacturing site (including all distributors) Robust supplier qualification and development programs that stand the test of time anticipate and mitigate risks Ability to detect anomalies limited testing is needed but tests have limitations Wolfgang, FDA, June 08

25 Supply Chain Controls Excipient Pedigree Do you know where all your ingredients are produced? Do you know how they were distributed? What evidence do you have which demonstrates this? More than One Up and One Down is needed!! What is your weakest link..? 24

26 Quality Agreements IPEC Guide Common starting point standard format, covers most fundamental quality issues specific to manufacture, distribution and use of excipients Puts both parties on the two-way street Reduces time & effort needed to reach agreement Individual company agreements frequently designed to cover multiple types of products (APIs, excipients, packaging) different needs! Gets more successful quality agreements in place The benefits can t be realized until the agreement is in place! The information contained in this presentation is proprietary to Colorcon and may not be used or Copyright disseminated 2015, inappropriately. All Rights Reserved IPEC-Americas

27 IPEC Quality Agreement Guide Flexible model containing the appropriate topics for excipients. Complements, does not replace, commercial supply agreements. Not a substitute for supplier qualification processes or audits. Specifies specific quality commitments between the parties. Formalizes agreement on the quality standard that will be the basis of the QA. The information contained in this presentation is proprietary to Colorcon and may not be used or Copyright disseminated 2015, inappropriately. All Rights Reserved IPEC-Americas

28 Parties to Quality Agreements Quality agreements should cover the entire supply chain manufacturers, distributors, customers It is important to understand who in the chain is responsible for which quality activities

29 Supply Chain: Management & Mitigation Greater capabilities = lower risk to interruption of supply BCP Ingredient Design Controls Global Manufacturing & Technical Support Supplier Qualification & Change Control Programs Quality Management Systems Manufacturing & Distribution Number of Suppliers 28

30 Business Continuity (BCP) Formal Business Continuity Program Raw Materials Risk based approach to potential disruption of supply approved, mapped suppliers Alternate interchangeable suppliers identified for key raw materials Manufacturing Multiple Manufacturing Facilities Interchangeability Data for ALL Manufacturing Facilities Information Management Backup systems for all key data and control systems

31 CASE STUDY - What does Colorcon Do to Qualify and Control Suppliers and provide Value to Customers? 30

32 Management of Suppliers and Materials Supply Chain Management Product Development /Formulators Material Review Board Quality Assurance/ Quality Control Commercial Regulatory

33 Colorcon Raw Material and Supplier Qualification Process Material Request Materials Review Board Supplier Viability Check Regulatory requirements investigated Samples tested Specification Agreement Assign Risk Category Add to cgmp routine Audit schedule Supplier Questionnaire Qualification / Capability Audit Materials Review Board Approve for Use

34 Supplier Assessment and Qualification Supplier Qualification Process: Supply Chain Viability Check List Supplier Qualification Questionnaire and supporting documentation Quality management system registration IPEC site quality overview (EIP) Other certifications Distributor Qualification Questionnaire Supplier Approval Form The process also includes a physical audit where necessary using the IPEC/PQG & IFAC GMP guides as a reference standard

35 Material Compliance Formal specification agreement with supplier Assessment against official standards does it meet the correct compendia, food standard or other regulatory requirements? Colorcon specification requirements e.g. color, particle size, physical characteristics Other regulatory attributes e.g. GMO status, BSE/TSE status, Kosher, allergens Three batch samples are requested and are subjected to: Full regulatory (ie; 21CFR, E#) and compendial analysis for the target markets Colorcon product specification analysis including any performance based tests/limits which may be needed for the intended use at Colorcon Comparison vs supplier s reported results and typical values from current source Where necessary, performance and stability testing in model products

36 Supply Chain Mapping Every Supply Chain is fully mapped Control inbuilt into Colorcon Business Systems purchasing & receiving processes mandate approved suppliers only Colorcon s Global Watch management system established to assess and understand the potential impact of environmental and political events and vulnerability

37 Supply Chain Map Manufacturer X Manufacturer X Site (location DE) This example shows one manufacturing location that supplies Colorcon sites directly and through multiple distribution routes. Distributor (US) Distributor (CN) Distributor (IN) Colorcon West Point (US) Colorcon Dartford (UK) Colorcon Shanghai (CN) Colorcon Goa (IN) Colorcon Humacao (PR) Colorcon Japan (JP) There is more complexity for a raw material with interim processing or repacking in the chain.

38 Global Watch Canada 6 Europe 120 USA 233 West Indies 2 Japan 43 China 7 South Korea 6 India 11 Thailand 1 Taiwan 1 Mexico 1 Belize 2 Peru 6 South America 1 Brazil 6 Ghana 1 Ivory Coast 1 Cameroon 1 Africa 2 Tanzania 2 Mauritius 2 Swaziland 2 Singapore 1 Malaysia 8 Philippines 1 Indonesia 4 Fiji 2

39 Impact Analysis (eg. Japan Supply Chain Map) Within 24 hours we were able to establish which suppliers were impacted, contact them and understand the status of their facilities. 30 KM exclusion zone G A C I J L N M B F E K H F D O B

40 Supply Chain Map: Colorcon to Customer Colorcon Site Colorcon Approved Carrier Customer s Carrier Customer

41 Risk Management GMP audit Change control process Warehouse & carrier audit Risk Management MRB Vendor performance monitoring Supplier issue management

42 Business Continuity Plan (BCP) Managing multiple source and manufacturing locations Alternative manufacturing site from same supplier Maintains consistency Qualified interchangeable material Colorcon has multiple manufacturing sites & distribution centres around the world..

43 Business Continuity: Interchangeable Facilities Puerto Rico West Point, USA Dartford, UK Shanghai, China Goa, India Nishiyama, Japan Interchangeable Dispersion Facilities Brazil Coming Soon!! 42

44 Colorcon Global Manufacturing and Distribution Facilities Manufacturing Distribution DARTFORD, UK BAZAINVILLE, FR STOUGHTON,WI INDIANAPOLIS, IN IRVINE, CA WEST POINT, PA SEOUL, KR SHANGHAI, CN NISHIYAMA, JP HUMACAO, PR GOA, IN CUAJIMAIPA, MX CARACAS, VE BOGOTA, CO SINGAPORE COTIA, BR SANTIAGO, CL BUENOS AIRES, AR Global Capability - BCP

45 Ensure Your Supply Chain Security Establish Your Suppliers of Choice Carefully!

46 Questions 45

Regulatory Perspective on Assuring Ingredient Quality

Regulatory Perspective on Assuring Ingredient Quality Regulatory Perspective on Assuring Ingredient Quality PQRI Conference December 15, 2009 Rockville, MD Steven M. Wolfgang, Ph.D., Acting Associate Director, Regulatory Science US Food and Drug Administration

More information

Increasing Focus on Excipients

Increasing Focus on Excipients The New Paradigm for Excipient Qualification and Supply Chain Control IPEC Update David R. Schoneker Director of Global Regulatory Affairs - Colorcon Chairman International Pharmaceutical Excipients Council

More information

IPEC Present & Future. Excipient Fest Janeen Skutnik Chair IPEC Americas

IPEC Present & Future. Excipient Fest Janeen Skutnik Chair IPEC Americas IPEC Present & Future Excipient Fest Janeen Skutnik Chair IPEC Americas 1 IPEC Background IPEC Activities Potential Legislative & Regulatory Actions Future Initiatives 2 IPEC Mission To collaborate with

More information

EMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems. Jan Thomsen Warsaw, November 15 th, 2016

EMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems. Jan Thomsen Warsaw, November 15 th, 2016 EMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems Jan Thomsen Warsaw, November 15 th, 2016 2 Content Emprove - An Introduction Emprove for Raw and Starting Materials

More information

Quality Risk Management: Excipients

Quality Risk Management: Excipients Quality Risk Management: Excipients ExcipientFest 2012 Presented by: Londa Ritchey, M.S. Director, Supplier Qualification Global Quality Operations Pfizer, Inc. Agenda Regulatory Environment Material Quality

More information

The Importance of Supplier Qualification of the Full Distribution Life-cycle in Pharmaceuticals

The Importance of Supplier Qualification of the Full Distribution Life-cycle in Pharmaceuticals The Importance of Supplier Qualification of the Full Distribution Life-cycle in Pharmaceuticals William Dale Carter IPEC Americas Chair-Elect & GMP Committee Chair ExcipientFest April 25, 2012 www.ipecamericas.org

More information

The Impact of Excipient Variability on QbD The Need for Good Qualification Processes IPEC America s Perspective

The Impact of Excipient Variability on QbD The Need for Good Qualification Processes IPEC America s Perspective The Impact of Excipient Variability on QbD The Need for Good Qualification Processes IPEC America s Perspective David Schoneker Director of Global Reg. Affairs Colorcon Chairman IPEC Americas Phone: 215-661-2513

More information

excipients Setting the Scene

excipients Setting the Scene NSF/IPEC/ANSI 363: Good Manufacturing Practices (GMP) for Pharmaceutical Excipients Multiple stakeholders; one objective. Presented by Janeen Skutnik-Wilkinson International Pharmaceutical Excipients Council

More information

Industry Perspective on Manufacturing in Early Development

Industry Perspective on Manufacturing in Early Development Industry Perspective on Manufacturing in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Eric Schmitt AbbVie IQ Drug Product Manufacturing Working Group August 2012 issue of Pharmaceutical

More information

Questionnaire Layout:

Questionnaire Layout: Raw Material Supplier Questionnaire Introduction: This questionnaire has been developed by the EHPM quality working group. It combines work carried out by EHPM various national associations in developing

More information

Best Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C.

Best Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Best Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Manufacturing Breakout Session 1 Survey Results: Drug Product Manufacturing

More information

Validation and Verification of Supply Chain: End-to-End Karen S Ginsbury For IVT: Workshop C 28 October :30 12:00

Validation and Verification of Supply Chain: End-to-End Karen S Ginsbury For IVT: Workshop C 28 October :30 12:00 Validation and Verification of Supply Chain: End-to-End Karen S Ginsbury For IVT: Workshop C 28 October 2014 08:30 12:00 Pangea 7 May 2014 Israel ONLY Pangea 7 May 2014 Israel ONLY Pangea 7 May 2014 Israel

More information

The IPEC Excipient Information Package (EIP): Template and User Guide

The IPEC Excipient Information Package (EIP): Template and User Guide The IPEC Excipient Information Package (EIP): Template and User Guide 2012 Page 1 of 13 FOREWORD IPEC is an international industry association formed in 1991 by manufacturers and end-users of excipients.

More information

International Pharmaceutical Excipients Council Of The Americas

International Pharmaceutical Excipients Council Of The Americas October 6, 2008 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Subject: FDA Draft Guidance for Industry, Residual Solvents in Drug

More information

Reference Standard Characterization. Steve Lane. General Manager, NSF Reference Standards.

Reference Standard Characterization. Steve Lane. General Manager, NSF Reference Standards. Reference Standard Characterization Steve Lane General Manager, NSF Reference Standards www.nsf-rs.org Regulatory Bodies will require that an Excipient: Be safe in the amount or dose used Meet applicable

More information

Supplier Oversight PQRI. September Steven Lynn, MS, CMQ/OE Vice President Global Quality Compliance Mylan

Supplier Oversight PQRI. September Steven Lynn, MS, CMQ/OE Vice President Global Quality Compliance Mylan Supplier Oversight September 2014 PQRI Steven Lynn, MS, CMQ/OE Vice President Global Quality Compliance Mylan Agenda Mylan Background Setting the Stage with a Scenario Current State Thinking Supplier Qualification

More information

CBER Expectations Regarding Contract Manufacturing

CBER Expectations Regarding Contract Manufacturing CBER Expectations Regarding Contract Manufacturing LCDR Qiao Bobo, Ph.D. FDA/CBER/OCBQ/DMPQ CASSS CMC Strategy Forum Summer 2014 Outline 2 Types of Cooperative Manufacturing Arrangements CBER Expectations

More information

Quality in Global Sourcing

Quality in Global Sourcing Quality in Global Sourcing Steve Greer Global Compliance Leader P&G Beauty & Grooming Current Challenges 1 Supplier Related Incidents High profile material contamination incidents have highlighted risks

More information

Inspection of API Manufacturers & Update on Registration Process

Inspection of API Manufacturers & Update on Registration Process Inspection of API Manufacturers & Update on Registration Process Catherine Neary, GMP Inspector GMP Conference 7 February 2017 Dublin Presentation Contents HPRA Inspection Programme for API Manufacturers

More information

SECTION L QUALITY ASSURANCE. 1) designating and managing quality control functions, including:

SECTION L QUALITY ASSURANCE. 1) designating and managing quality control functions, including: NT-L1.000 QUALITY ASSURANCE PROGRAM All NADOs shall have a QA Program. Current (2 nd Edition) NT-L1.100 BASIC ELEMENTS SECTION L QUALITY ASSURANCE The QA program shall include, at a minimum: 1) designating

More information

One non-numeric process related variable examined was post coating thermal (curing) treatment.

One non-numeric process related variable examined was post coating thermal (curing) treatment. Poster Reprint AAPS Annual Meeting November 27 Identification and Influence of Critical Coating Process Parameters on Drug Release from a Fully Formulated Aqueous Ethylcellulose Dispersion Charles F. Vesey,

More information

PHARMACEUTICAL AND BIOTECHNOLOGY UPDATE

PHARMACEUTICAL AND BIOTECHNOLOGY UPDATE Pharmaceutical and Biotechnology Update April 22, 2009 1 Hogan & Hartson LLP PHARMACEUTICAL AND BIOTECHNOLOGY UPDATE Current Trends in FDA s Pharmaceutical Good Manufacturing Practice (GMP) Warning Letters

More information

PHARMACEUTICAL AND BIOTECHNOLOGY UPDATE

PHARMACEUTICAL AND BIOTECHNOLOGY UPDATE Pharmaceutical and Biotechnology Update April 22, 2009 1 Hogan & Hartson LLP PHARMACEUTICAL AND BIOTECHNOLOGY UPDATE Current Trends in FDA s Pharmaceutical Good Manufacturing Practice (GMP) Warning Letters

More information

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Innovacion en Packaging Primario 1 Contents Company Highlight What s Changing in Pharma Pharma Trends Harmonisation New Requirements

More information

Multiple stakeholders; one objective. Atypical Actives Industry Perspective. USP Excipients Stakeholder Forum November 29, 2017

Multiple stakeholders; one objective. Atypical Actives Industry Perspective. USP Excipients Stakeholder Forum November 29, 2017 Atypical Actives Industry Perspective USP Excipients Stakeholder Forum November 29, 2017 Multiple stakeholders; one objective. Priscilla Zawislak Chair, IPEC-Americas pzawislak@dow.com International Pharmaceutical

More information

Regulatory. Supplier Qualification A Review

Regulatory. Supplier Qualification A Review Supplier Qualification A Review Abstract: It is a GMP requirement to certify the vendor to deliver high quality and safe medicines, and to prevent recalls, deaths, adverse events, and serious illness due

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Q8, Q9, and Q10 Questions and Answers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics

More information

Capillary Electrophoresis in Global Emerging Markets: A Regulatory Perspective. Brian K. Nunnally, Ph.D.

Capillary Electrophoresis in Global Emerging Markets: A Regulatory Perspective. Brian K. Nunnally, Ph.D. Capillary Electrophoresis in Global Emerging Markets: A Regulatory Perspective Brian K. Nunnally, Ph.D. Agenda The Lifecycle Approach a guidance review What it really means Global Emerging Markets and

More information

An essential guide to understanding the implications of product quality.

An essential guide to understanding the implications of product quality. An essential guide to understanding the implications of product quality. Kaat Bracquiné, Quality Control, Compliance and Regulatory Manager Capsugel EMEA Kim Weeks, Quality Assurance, Regulatory & Compliance

More information

Cambridge Commodities Ltd QUALITY MATTERS

Cambridge Commodities Ltd QUALITY MATTERS Cambridge Commodities Ltd QUALITY MATTERS contents Quality at CCL Meet the quality team New supplier and material approvals FTIR investigation Positive release Repack process Regulatory and technical support

More information

Lessons from Pharmaceutical Laboratory related FDA Warning Letters

Lessons from Pharmaceutical Laboratory related FDA Warning Letters Lessons from Pharmaceutical Laboratory related FDA Warning Letters The Agilent Critical Compliance Seminar 2016 Ludwig Huber Ludwig_huber@labcompliance.com Overview FDA Inspections and reports GMP compliance

More information

ISPE-FDA 3 rd Annual CGMP Conference 2 4 June 2014 Baltimore, MD. Detecting GMP Data Integrity Issues

ISPE-FDA 3 rd Annual CGMP Conference 2 4 June 2014 Baltimore, MD. Detecting GMP Data Integrity Issues Detecting GMP Data Integrity Issues Elaine Eborall Senior Director, GMP Compliance, Americas and Asia Pacific Compliance and External Collaboration ISPE-FDA cgmp Conference Baltimore, Maryland 2-4 June

More information

As discussed in Chapter 5, 21 CFR introduces the concept of and basic requirements for preventive controls. Recall that a preventive control

As discussed in Chapter 5, 21 CFR introduces the concept of and basic requirements for preventive controls. Recall that a preventive control (The supply chain program described in this chapter is not the same as a supply chain program typically thought of by the animal food industry. In fact, supplychain applied controls may have limited applicability

More information

DISTIBUTION CENTRES: WELCOME TO THE DANGER ZONE

DISTIBUTION CENTRES: WELCOME TO THE DANGER ZONE DISTIBUTION CENTRES: WELCOME TO THE DANGER ZONE Dr. Allen E. Goldenthal BSc,DVM,PhD,MBA January 24-25, 2019 DCVMN SEMINAR Shenzhen, China THE DISTRIBUTOR: A distributor, broker or agent is a type of supplier

More information

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible

More information

INGREDIENTS, FOOD SUPPLEMENTS AND NUTRITIONAL

INGREDIENTS, FOOD SUPPLEMENTS AND NUTRITIONAL INGREDIENTS, FOOD SUPPLEMENTS AND NUTRITIONAL COMPOUNDS SAFETY: THE QUALITY CONTROL OF RAW MATERIALS IN NUTRACEUTICALS, TO PREVENT CONSUMER HEALTH RISK GRF00000883 00 Supplier qualification of nutraceutical

More information

Impact of EU GMPs on Australian GMP. Trevor Schoerie PharmOut

Impact of EU GMPs on Australian GMP. Trevor Schoerie PharmOut Impact of EU GMPs on Australian GMP Trevor Schoerie PharmOut Part I Basic Requirements for Medicinal Products Current TGA Version, 7 years out of date TGA are actively and publically talking about PE009-0813

More information

What s New with the FSMA Rules? Co-Sponsored by:

What s New with the FSMA Rules? Co-Sponsored by: What s New with the FSMA Rules? Co-Sponsored by: What s New with the FSMA Rules David Gombas, Ph.D. June 12, 2014 Food Safety Modernization Act Fundamental changes in how FDA regulates food Generally supported

More information

Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel

Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel On February 13th, 2006, the FOOD AND DRUG ADMINISTRATION (FDA) implemented a revision to the Compliance Program Guidance Manual for active

More information

Health Authority Inspection Management. GMP Inspection practices L. Mansolelli, Group Compliance & Auditing June 2012

Health Authority Inspection Management. GMP Inspection practices L. Mansolelli, Group Compliance & Auditing June 2012 Health Authority Inspection Management GMP Inspection practices L. Mansolelli, Group Compliance & Auditing June 2012 Abstract As global health authorities align in inspection standards and practices, key

More information

San Jose, California, USA

San Jose, California, USA Glisland, Inc. San Jose, California, USA http://www.glisland.com Welcome to the Drug GMP World Current Good Manufacturing Practice cgmp ICH Q10 Pharmaceutical Quality System PQS GMP QSR Quality System

More information

Q&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document

Q&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document Q&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document March 2017 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 ICH Q7 - Questions

More information

Quality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals

Quality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals Quality Agreements with CMO s Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals FDA Guidance Contract Manufacturing Arrangements for Drugs: Quality

More information

Implementation of EU Falsified Medicines Directive

Implementation of EU Falsified Medicines Directive Implementation of EU Falsified Medicines Directive Gerald W Heddell Director, Inspection, Enforcement & Standards Division 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The views

More information

GMP Challenges to Global Pharma Companies

GMP Challenges to Global Pharma Companies GMP Challenges to Global Pharma Companies Muralidhara B. Gavini, Ph.D. Senior Assistant Country Director India Mumbai Office, Office of International Programs Office of the Commissioner Food & Drug Administration

More information

Final Rule on Foreign Supplier Verification Programs.

Final Rule on Foreign Supplier Verification Programs. Final Rule on Foreign Supplier Verification Programs http://www.fda.gov/fsma 1 Background FSMA Sec. 301 requires importers to have FSVPs and FDA to issue regulations. Proposed rule: July 29, 2013 Supplemental

More information

An FDA Perspective on Atypical Active Ingredients

An FDA Perspective on Atypical Active Ingredients An FDA Perspective on Atypical Active Ingredients Presented by Steven Wolfgang, Ph.D. Center for Drug Evaluation and Research Office of Compliance Office of Drug Security, Integrity and Response steven.wolfgang@fda.hhs.gov

More information

GOOD MANUFACTURING PRACTICES - AUDIT REPORT FORM AKA GMP Standards Program

GOOD MANUFACTURING PRACTICES - AUDIT REPORT FORM AKA GMP Standards Program GOOD MANUFACTURING PRACTICES - AUDIT REPORT FORM AKA GMP Standards Program HC USE ONLY File Number Date/Time of Receipt To be completed by an Independent 3 rd Party Auditor. GENERAL INFORMATION A. Submission

More information

Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance

Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance by Tom Savage, NSF International Since 2008, when patient deaths were first linked to

More information

Counterfeit Drugs and Supply Chain Security

Counterfeit Drugs and Supply Chain Security Counterfeit Drugs and Supply Chain Security Rick Mitzner Senior Director, Engineering Technology Pfizer, Inc. Interphex April 21, 2015 Tragic Consequences Not If But When and Where May 7, 2007 80 children

More information

While the recognition

While the recognition Designing the Perfect Change Control System Change control systems today are expected to be designed in a way that provides a system to not only document and approve changes, but also to anticipate change

More information

Foreign Supplier Verification Programs: The Final Rule.

Foreign Supplier Verification Programs: The Final Rule. Foreign Supplier Verification Programs: The Final Rule http://www.fda.gov/fsma 1 Background FSMA Sec. 301 requires importers to have FSVPs and FDA to issue regulations. Proposed rule: July 29, 2013 Supplemental

More information

QUALITY AGREEMENT. The following Agreement has been concluded between

QUALITY AGREEMENT. The following Agreement has been concluded between QUALITY AGREEMENT The following Agreement has been concluded between LLC LABORATORIES The contract laboratory and service provider 1625 Trinity Dr., Unit 11 Mississauga, Ontario Canada L5T 1W9 Hereinafter

More information

National Animal Supplement Council

National Animal Supplement Council NASC established a Preferred Supplier Program for companies who wish to provide products and services to NASC member companies, including raw materials (ingredients), contract manufacturing (dosage form

More information

The IPEC Quality Agreement Guide and Template

The IPEC Quality Agreement Guide and Template The IPEC Quality Agreement Guide and Template 2009 This document represents voluntary guidance for the pharmaceutical excipient industry and the contents should not be interpreted as regulatory requirements.

More information

Subpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.

Subpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit. FDA inspections continue to focus on CGMP violations related to basic GMP controls. A survey of Warning Letters issued in 2013 on CMC (Chemistry / Manufacturing / Controls) violations reveals an emphasis

More information

GxP Auditing, Remediation, and Quality System Resourcing

GxP Auditing, Remediation, and Quality System Resourcing GxP Auditing, Remediation, and Quality System Resourcing TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing

More information

PURITAN PRODUCTS QUALITY OVERVIEW. Quality Management System Self-Audit. September 15, 2015

PURITAN PRODUCTS QUALITY OVERVIEW. Quality Management System Self-Audit. September 15, 2015 PURITAN PRODUCTS QUALITY OVERVIEW Quality Management System Self-Audit September 15, 2015 Founded in 1987, Puritan Products, Inc. is a cgmp compliant, FDA registered and inspected, and ISO-9001:2008 certified

More information

Regulatory expectations on impurities in drug substances - Pavia, October 2, Luisa Torchio Euticals SpA

Regulatory expectations on impurities in drug substances - Pavia, October 2, Luisa Torchio Euticals SpA Regulatory expectations on impurities in drug substances - Pavia, October 2, 2015 Luisa Torchio Euticals SpA An Impurity is defined as any substance or element present in a drug substance (DS) that is

More information

Quality Implementation Working Group on Q8, Q9 and Q10 Questions & Answers

Quality Implementation Working Group on Q8, Q9 and Q10 Questions & Answers INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Quality Implementation Working Group on Q8, Q9 and Q10 & Current version dated June

More information

A Life Cycle Approach to Raw Material Qualification for Cell and Gene Therapy Products

A Life Cycle Approach to Raw Material Qualification for Cell and Gene Therapy Products A Life Cycle Approach to Raw Material Qualification for Cell and Gene Therapy Products Angela Whatley, Ph.D. Office of Tissues and Advanced Therapies CBER/FDA CMC Strategy Forum on Cell & Gene Therapies

More information

Control strategy and validation. Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA

Control strategy and validation. Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA Control strategy and validation Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA 1 Disclaimer The views and opinions expressed in this presentation are those of the speaker and should not

More information

DATA INTEGRITY ASSURANCE AS KEY FACTOR FOR SURVIVING CORPORATE AUDITS AND REGULATORY INSECTIONS

DATA INTEGRITY ASSURANCE AS KEY FACTOR FOR SURVIVING CORPORATE AUDITS AND REGULATORY INSECTIONS GLOBAL PROVIDER, LOCAL SOLUTIONS IN YOUR LANGUAGE DATA INTEGRITY ASSURANCE AS KEY FACTOR FOR SURVIVING CORPORATE AUDITS AND REGULATORY INSECTIONS Francesco Amorosi PhD Octorber 2017 DATA INTEGRITY & CSV:

More information

Taking a Leap Toward Global Supply Chain Efficiency - Part II

Taking a Leap Toward Global Supply Chain Efficiency - Part II Taking a Leap Toward Global Supply Chain Efficiency - Part II 2 Supply Chain Brochure - Part II INTRODUCTION Pharmaceutical manufacturers face a number of challenges in the production and delivery of medicinal

More information

GMP The Other Side of Chemistry, Manufacturing & Controls (CMC)

GMP The Other Side of Chemistry, Manufacturing & Controls (CMC) Overview of USFDA Drug Regulatory Requirements Pharmaceutical Quality and Facility Inspections (GMP) Session II 19 February 2014 Casablanca, Morocco GMP The Other Side of Chemistry, Manufacturing & Controls

More information

Spirax Sarco. Clean steam overview

Spirax Sarco. Clean steam overview Spirax Sarco Clean steam overview Spirax Sarco - investing in solutions for clean systems Clean steam has been an important part of Spirax Sarco s business since pioneering the development of the BT6,

More information

GAMP5 Validation for Dynamics 365

GAMP5 Validation for Dynamics 365 GAMP5 Validation for Dynamics 365 Prepared by: Michael Webster, Business Development Director, RSM US LLP michael.webster@rsmus.com, +1 617 241 1544 Dynamics 365 is an ideal enterprise resource planning

More information

Initiatives in fiscal 2015 and beyond

Initiatives in fiscal 2015 and beyond Initiatives in fiscal 2015 and beyond The 2014 2016 Ajinomoto Group Medium-Term Plan for Quality Assurance, continuing from previous years, sets out three guidelines: Keep faith with customers, Fulfill

More information

RECOMMENDATIONS FOR DIETARY INGREDIENT PROCESSORS

RECOMMENDATIONS FOR DIETARY INGREDIENT PROCESSORS RECOMMENDATIONS FOR DIETARY INGREDIENT PROCESSORS Facilities that manufacture 117, pack, or hold dietary supplements are subject to the regulations in 21 CFR Part 111, while those that manufacture, pack,

More information

Ensuring Quality of Donated Medicines and Supplies during a Global Health Emergency

Ensuring Quality of Donated Medicines and Supplies during a Global Health Emergency Ensuring Quality of Donated Medicines and Supplies during a Global Health Emergency May 2018 Christine Chacko Public Sector During times of global health emergency, the potential to introduce substandard

More information

DOW PuraGuard Propylene Glycol USP/EP. Your Security for Purity

DOW PuraGuard Propylene Glycol USP/EP. Your Security for Purity DOW PuraGuard Propylene Glycol USP/EP Your Security for Purity Purity Plus A very high dedication to consistent quality and purity governs the entire product supply process for DOW PuraGuard Propylene

More information

Most Common Deficiencies Found. Dr Florence Benoit-Guyod Head of the inspection section Certification of Substances Department

Most Common Deficiencies Found. Dr Florence Benoit-Guyod Head of the inspection section Certification of Substances Department Most Common Deficiencies Found by EDQM Dr Florence Benoit-Guyod Head of the inspection section Certification of Substances Department Overview Fact & Figures Main deficiencies Conclusion 2 Inspection figures

More information

HACCP audit checklist

HACCP audit checklist Requirement HACCP audit checklist Prerequisite Program Management Commitment 1. Senior management ensures that the responsibilities and authorities are defined and communicated within the company Internal

More information

Outsourcing - managing risks and opportunities over which you now have less control

Outsourcing - managing risks and opportunities over which you now have less control Outsourcing - managing risks and opportunities over which you now have less control Kevin O Donnell, PhD PDA Meeting, Dublin 22 nd November 2018 Slide 2 Typical Examples The key GMP Requirements & Guidance

More information

Enforcement of Compliance with GMPs in API manufacture

Enforcement of Compliance with GMPs in API manufacture Enforcement of Compliance with GMPs in API manufacture Guy Villax Copyright Hovione 2004 No one is more active in pharmaceutical ingredients Agenda What are APIs, GMP What is the legal framework What is

More information

Phase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017

Phase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 Phase Appropriate GMPs for IMPs Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 1 Lets start with References https://mhrainspectorate.blog.gov.uk/2016/0 5/20/manufacture-of-investigationalmedicinal-products-frequently-askedquestions/

More information

Serving Patients is a Privilege

Serving Patients is a Privilege Serving Patients is a Privilege This Privilege Comes with Significant Responsibilities Understanding Requirements for Data Integrity How to Develop a Data Integrity Program Including Data Integrity with

More information

Regulatory Update. Paul Sexton. QP Forum

Regulatory Update. Paul Sexton. QP Forum Regulatory Update Paul Sexton QP Forum 16 th April, 2015 Content Updates on GMP Guidance Updates on EU Legislation Draft Ph Eur monograph on WFI including RO 2 Chapter 5 - Production Paragraphs 27 to 30

More information

Good Manufacturing Practices Purpose and Principles of GMP. Tony Gould

Good Manufacturing Practices Purpose and Principles of GMP. Tony Gould Good Manufacturing Practices Purpose and Principles of GMP Tony Gould Why GMP? Provides a high level assurance that medicines are manufactured in a way that ensures their safety, efficacy and quality Medicines

More information

Certification in Central and Eastern Europe

Certification in Central and Eastern Europe Certification in Central and Eastern Europe Timber Regulation Enforcement Exchange Vienna, 16 September 2015 Dirk Teegelbekkers General Secretary PEFC Germany www.pefc.org www.pefc.org Overview Introduction

More information

ORGANIC ENSURING GLOBAL ORGANIC SUPPLY CHAIN INTEGRITY EXECUTIVE SUMMARY GUIDE. Fraud Prevention

ORGANIC ENSURING GLOBAL ORGANIC SUPPLY CHAIN INTEGRITY EXECUTIVE SUMMARY GUIDE. Fraud Prevention EXECUTIVE SUMMARY ORGANIC Fraud Prevention GUIDE ENSURING GLOBAL ORGANIC SUPPLY CHAIN INTEGRITY A Guide to Developing an Organic Fraud Prevention Plan An Organic Trade Association Resource Ensuring Global

More information

Quality Risk Management (ICH Q9): WHO Model for Sustainable Quality Medicines

Quality Risk Management (ICH Q9): WHO Model for Sustainable Quality Medicines Quality Risk Management (ICH Q9): WHO Model for Sustainable Quality Medicines Longe Sunday Anthony Head- Quality Assurance May & Baker Nigeria Plc. Pharmacentre, Ota, Nigeria eaglesconsult@gmail.com; Slonge@may-

More information

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer Part 1: General information Name of Manufacturer Production Block Physical address Contact address Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer. Clean Utilities in the Basement.

More information

Develop and Implement Contingency Plans to Better Prepare for Unexpected Events

Develop and Implement Contingency Plans to Better Prepare for Unexpected Events Develop and Implement Contingency Plans to Better Prepare for Unexpected Events CBI s Biopharmaceutical Forum on Clinical and Commercial Supply Chain Excellence Jul 24-25 2012 New Brunswick, NJ BioProcess

More information

GxP Auditing, Remediation, and Staff Augmentation

GxP Auditing, Remediation, and Staff Augmentation GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 5 GLP Auditing 6 Pharmacovigilance Auditing 6 Vendor/Supplier Auditing 7

More information

MEASURE FOR MEASURE: QUALITY METRICS

MEASURE FOR MEASURE: QUALITY METRICS MEASURE FOR MEASURE: QUALITY METRICS PDA Midwest Chapter Dinner Meeting, Northbrook, IL-9 November 2017 Felicia Ford-Rice, Director, Strategic Compliance 2017 PAREXEL INTERNATIONAL CORP. AGENDA Robust

More information

U.S. FSMA Seminar: Practices

U.S. FSMA Seminar: Practices U.S. FSMA Seminar: Practices Case Studies 1 Q1 Registration of Food Facility Company A contracts out production to Company B and Company C. 1. Which company is responsible for applying to a facility registration?

More information

SUPPLIER FOOD SAFETY ASSURANCE

SUPPLIER FOOD SAFETY ASSURANCE Chapter 12 SUPPLIER FOOD SAFETY ASSURANCE 1.0 PARTS OF A SUPPLIER FOOD SAFETY ASSURANCE PROGRAM 2.0 CHOOSING SUPPLIERS 2.1 Supplier Approval 2.2 Approved Supplier List 3.0 PRODUCT SPECIFICATIONS AND CONTROLS

More information

Quality Agreements and Managing Contract Supplier Quality

Quality Agreements and Managing Contract Supplier Quality Quality Agreements and Managing Contract Supplier Quality American Society for Quality Lloyd Bailey November 3, 2005 Service Mark of The Dow Chemical Company TM Trademark of The Dow Chemical Company Abstract

More information

(Information) INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION

(Information) INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION 21.3.2015 EN Official Journal of the European Union C 95/1 II (Information) INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION Guidelines of 19 March 2015 on

More information

Supplier Assurance Program. CBE Pty Ltd

Supplier Assurance Program. CBE Pty Ltd Supplier Assurance Program CBE Pty Ltd This training program is copyright to CBE Pty Ltd and may not be modified, reproduced, sold, loaned, hired or traded in any form without its express written permission.

More information

21CFR Ventilation, air filtration, air heating and cooling. 21CFR211 Details, Details. 21CFR Equipment Cleaning and Maintenance

21CFR Ventilation, air filtration, air heating and cooling. 21CFR211 Details, Details. 21CFR Equipment Cleaning and Maintenance 21CFR211 Details, Details Kirsten L. Vadheim, Ph.D., RAC 7710 196th Avenue N.E. Redmond WA 98053 Tel: 651.260.6560 Fax: 425.868.4302 klvadheim@hotmail.com 21CFR211.46 Ventilation, air filtration, air heating

More information

Perspective. Supply Chain Management (SQM) Risk Assessing Your Supply Chain

Perspective. Supply Chain Management (SQM) Risk Assessing Your Supply Chain Perspective Supply Chain Management (SQM) Risk Assessing Your Supply Chain What is Risk? the scientific evaluation of known or potential adverse health effects resulting from human exposure to foodborne

More information

ORC Sponsor-Investigator IDE Checklist

ORC Sponsor-Investigator IDE Checklist A sponsor-investigator assumes BOTH investigator and sponsor responsibilities as outlined in the FDA Code of Federal Regulations 21CFR812. This means that such investigators have additional responsibilities.

More information

Proposed Rules to Help Ensure the Safety of Imported Food.

Proposed Rules to Help Ensure the Safety of Imported Food. Proposed Rules to Help Ensure the Safety of Imported Food http://www.fda.gov/fsma 1 Why Are These Proposed Rules Important? About 15 percent of the U.S. food supply is imported including nearly 50 percent

More information

New GMPs for Active Substances & Excipients. Presented by Eoin Hanley 4 July, 2016

New GMPs for Active Substances & Excipients. Presented by Eoin Hanley 4 July, 2016 New GMPs for Active Substances & Excipients Presented by Eoin Hanley 4 July, 2016 What we will cover in this session The changing landscape EC Guideline on principles of GDP of active substances Formalised

More information

Annex 6. Good trade and distribution practices for pharmaceutical starting materials

Annex 6. Good trade and distribution practices for pharmaceutical starting materials Annex 6 Good trade and distribution practices for pharmaceutical starting materials Introduction 212 1. Quality management 213 2. Organization and personnel 214 3. Premises 215 4. Procurement, warehousing

More information

Excipient Certification: Schemes and Auditable Standards - the role in Supplier Qualification

Excipient Certification: Schemes and Auditable Standards - the role in Supplier Qualification Excipient Certification: Schemes and Auditable Standards - the role in Supplier Qualification European Compliance Academy Vienna, 20 th & 21 st October 2009 Dr Iain Moore Chair Certification Committee

More information

GxP Auditing, Remediation, and Staff Augmentation

GxP Auditing, Remediation, and Staff Augmentation GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing 8

More information